Policy & News
Domestic clinical trial approved for bivalent mRNA vaccine against Emmy vaccine
2023-07-03
Aimé Vaccines announced on the Hong Kong Stock Exchange on 29 June that the company's bivalent mRNA New Crown vaccine for the Delta and Omicron BA.5 variants under development has been approved for clinical trials by the State Drug Administration. Research data has shown that this vaccine shows high level of neutralising antibodies against the XBB mutant strain.
View More
2023-06-25
Circular of the Drug Review Centre of the State Drug Administration on the Publication of the Technical Guidelines for Clinical Trials of Human-Derived Stem Cells and Their Derived Cellular Therapeutic Products (for Trial Implementation) (No. 37 of 2023)
View More
2023-06-13
On June 10, information on the official website of the Centre for Drug Evaluation (CDE) of the State Drug Administration showed that the application for clinical trial of human rabies mRNA vaccine of Livanda Biologicals, a subsidiary of domestic private vaccine maker Aimee Vaccines, has been accepted. This signifies that the first rabies mRNA vaccine declared for clinical use in China is expected to enter the clinic soon.
View More
2023-06-13
On 8 June 2023, the recombinant trivalent neocoronavirus (XBB.1.5+BA.5+Delta variant) trimeric protein vaccine (Sf9 cells) developed by Wisker Biotech/Chuan Da Huaxi - Wikxin® 3-valent XBB vaccine was included in the emergency use with the approval of the relevant state departments, which is the world's first neocoronavirus vaccine approved for emergency use against the mutant strains of XBB and other mutants, marking that China's This is the first new crown vaccine approved for emergency use in the world against XBB and other mutant strains, signifying that China's research and development of new crown vaccines has been at the forefront of the world.
View More
Heavyweight! mRNA vaccine combination therapy reduces melanoma death risk by 65%!
2023-06-06
On 5 June, mRNA vaccine giants Moderna and Merck Sharp & Dohme announced at the 2023 ASCO Annual Meeting that a Phase 2b study of the combination of the individualised oncology vaccine, mRNA-4157 (V940), and the anti-PD-1 therapy, Keytruda, demonstrated that the combination therapy, used in patients with surgically resected, high-risk melanoma (Stage III/IV), reduced the risk of spreading or dying from this skin cancer by 65%, compared to Keytruda alone.
View More
2023-06-05
The Implementing Rules of the Regulations on Human Genetic Resources Management have been considered and adopted at the 3rd Ministerial Meeting of the Ministry of Science and Technology on 11 May 2023, and are hereby promulgated and shall come into force on 1 July 2023.
View More
